Department of Cardiology, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, the Netherlands.
Europace. 2011 Oct;13(10):1454-8. doi: 10.1093/europace/eur136. Epub 2011 May 11.
Coronary sinus (CS) lead placement for transvenous cardiac resynchronization therapy (CRT) even combined with transseptal left ventricular (LV) endocardial implantation from a superior approach still does not have 100% success rate. The aim of this study was to assess the feasibility of a femoral transseptal endocardial LV approach pacing in patients in whom a transvenous CS or a transseptal LV endocardial implantation with a superior approach had failed. We report our first experience with LV endocardial lead placement for CRT with a femoral transseptal technique followed by intravascular pull-through to the pectoral location.
In 11 patients, 10 males (61.5 ± 9.5 years) with failed CS implant (four patients) or repeated CS lead malfunction (seven patients), a 4.1 French active fixation lead was implanted endocardially in the left ventricle employing a femoral approach using an 8F transseptal sheath combined with a hooked 6F catheter. After successful implantation, the lead was pulled through from the femoral insertion site to the pectoral device location. The LV endocardial implantation was successfully performed in all patients. Stimulation threshold was 0.62 ± 0.33 V, lead impedance 825 ± 127 Ω, and R wave 12.8 ± 8.3 mV. Threshold and lead impedance were stable during follow-up, which varied from 1 to 6 months. No dislodgements were observed and there were no thrombo-embolic events during follow-up.
This technique for LV endocardial lead implantation is an alternative for failed CS and superior transseptal attempts using standard techniques and equipment. It is also applicable for pacing sites that are more easily reached from a femoral approach.
冠状窦(CS)导联放置用于经静脉心脏再同步治疗(CRT),即使结合从上方入路的经间隔左心室(LV)心内膜植入,其成功率仍未达到 100%。本研究旨在评估在经静脉 CS 或经间隔上方入路 LV 心内膜植入失败的患者中,经股静脉经间隔心内膜 LV 起搏的可行性。我们报告了首例使用股静脉经间隔技术进行 LV 心内膜导联放置以进行 CRT 的经验,随后将导引导管经血管内拉至胸壁位置。
在 11 例患者中,10 例男性(61.5±9.5 岁)CS 植入失败(4 例)或 CS 导联反复故障(7 例),采用股静脉途径,使用 8F 经间隔鞘管和带钩 6F 导管,将 4.1Fr 主动固定导联在心内膜内植入左心室。成功植入后,将导引导管从股静脉插入部位拉至胸壁装置位置。所有患者均成功进行 LV 心内膜植入。刺激阈值为 0.62±0.33V,导联阻抗 825±127Ω,R 波 12.8±8.3mV。阈值和导联阻抗在随访期间保持稳定,随访时间为 1 至 6 个月。未观察到脱位,随访期间无血栓栓塞事件。
该技术用于 LV 心内膜导联植入是一种替代方法,适用于经静脉 CS 和上方入路的经间隔尝试失败的患者,使用标准技术和设备。它也适用于更易于从股静脉入路到达的起搏部位。